Theriva Biologics Inc. (TOVX) - Net Assets
Based on the latest financial reports, Theriva Biologics Inc. (TOVX) has net assets worth $15.40 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($38.25 Million) and total liabilities ($22.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TOVX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.40 Million |
| % of Total Assets | 40.26% |
| Annual Growth Rate | 7.33% |
| 5-Year Change | -76.48% |
| 10-Year Change | 583.99% |
| Growth Volatility | 256.21 |
Theriva Biologics Inc. - Net Assets Trend (1993–2025)
This chart illustrates how Theriva Biologics Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Theriva Biologics Inc. for the complete picture of this company's asset base.
Annual Net Assets for Theriva Biologics Inc. (1993–2025)
The table below shows the annual net assets of Theriva Biologics Inc. from 1993 to 2025. For live valuation and market cap data, see Theriva Biologics Inc. stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $15.38 Million | -19.32% |
| 2024-12-31 | $19.07 Million | -51.97% |
| 2023-12-31 | $39.70 Million | -27.25% |
| 2022-12-31 | $54.56 Million | -16.58% |
| 2021-12-31 | $65.41 Million | +1143.97% |
| 2020-12-31 | $5.26 Million | -54.23% |
| 2019-12-31 | $11.49 Million | -56.58% |
| 2018-12-31 | $26.45 Million | +875.81% |
| 2017-12-31 | $-3.41 Million | -251.62% |
| 2016-12-31 | $2.25 Million | -85.01% |
| 2015-12-31 | $15.00 Million | +57.00% |
| 2014-12-31 | $9.56 Million | -37.26% |
| 2013-12-31 | $15.23 Million | +16.90% |
| 2012-12-31 | $13.03 Million | +84.56% |
| 2011-12-31 | $7.06 Million | +97.26% |
| 2010-12-31 | $3.58 Million | +0.97% |
| 2009-12-31 | $3.54 Million | -47.61% |
| 2008-12-31 | $6.76 Million | -43.37% |
| 2007-12-31 | $11.95 Million | +1.35% |
| 2006-12-31 | $11.79 Million | +1774.59% |
| 2005-12-31 | $-703.84K | +95.43% |
| 2002-12-31 | $-15.39 Million | -69.33% |
| 2001-12-31 | $-9.09 Million | -2096.24% |
| 2000-12-31 | $-413.72K | -161.65% |
| 1999-12-31 | $671.07K | -4.13% |
| 1998-12-31 | $700.00K | +131.82% |
| 1997-12-31 | $-2.20 Million | -229.41% |
| 1996-12-31 | $1.70 Million | -5.56% |
| 1995-12-31 | $1.80 Million | +460.00% |
| 1994-12-31 | $-500.00K | -131.25% |
| 1993-12-31 | $1.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Theriva Biologics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35281000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $34.00K | 0.22% |
| Other Comprehensive Income | $755.00K | 4.91% |
| Other Components | $373.30 Million | 2426.73% |
| Total Equity | $15.38 Million | 100.00% |
Theriva Biologics Inc. Competitors by Market Cap
The table below lists competitors of Theriva Biologics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Noida Toll Bridge Company Limited
NSE:NOIDATOLL
|
$13.61 Million |
|
CMX GOLD+SILVER CORP.
F:6GS
|
$13.61 Million |
|
Pan Asia Footwear Public Company Limited
BK:PAF
|
$13.63 Million |
|
Savannah Goldfields Ltd
AU:SVG
|
$13.64 Million |
|
FIPP S.A.
PA:FIPP
|
$13.61 Million |
|
Pegasus Heights Bhd
KLSE:4464
|
$13.58 Million |
|
Physitrack PLC
ST:PTRK
|
$13.58 Million |
|
Investsmart Group Ltd
AU:INV
|
$13.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Theriva Biologics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,067,000 to 15,383,000, a change of -3,684,000 (-19.3%).
- Net loss of 25,249,000 reduced equity.
- New share issuances of 13,523,000 increased equity.
- Other comprehensive income increased equity by 1,933,000.
- Other factors increased equity by 6,109,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.25 Million | -164.14% |
| Share Issuances | $13.52 Million | +87.91% |
| Other Comprehensive Income | $1.93 Million | +12.57% |
| Other Changes | $6.11 Million | +39.71% |
| Total Change | $- | -19.32% |
Book Value vs Market Value Analysis
This analysis compares Theriva Biologics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.23x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $-510.03 | $0.30 | x |
| 2006-12-31 | $1271.59 | $0.30 | x |
| 2007-12-31 | $237.60 | $0.30 | x |
| 2008-12-31 | $114.65 | $0.30 | x |
| 2009-12-31 | $58.19 | $0.30 | x |
| 2010-12-31 | $55.93 | $0.30 | x |
| 2011-12-31 | $89.16 | $0.30 | x |
| 2012-12-31 | $130.67 | $0.30 | x |
| 2013-12-31 | $116.73 | $0.30 | x |
| 2014-12-31 | $53.99 | $0.30 | x |
| 2015-12-31 | $69.61 | $0.30 | x |
| 2016-12-31 | $14.27 | $0.30 | x |
| 2017-12-31 | $-4.21 | $0.30 | x |
| 2018-12-31 | $47.11 | $0.30 | x |
| 2019-12-31 | $8.74 | $0.30 | x |
| 2020-12-31 | $4.22 | $0.30 | x |
| 2021-12-31 | $5.37 | $0.30 | x |
| 2022-12-31 | $89.00 | $0.30 | x |
| 2023-12-31 | $61.61 | $0.30 | x |
| 2024-12-31 | $14.14 | $0.30 | x |
| 2025-12-31 | $1.27 | $0.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Theriva Biologics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -164.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.49x
- Recent ROE (-164.14%) is above the historical average (-286.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | -229.41% | -3900.00% | 0.06x | 1.06x | $-4.07 Million |
| 1994 | 0.00% | -6300.00% | 0.25x | 0.00x | $-6.24 Million |
| 1995 | -411.11% | -7400.00% | 0.05x | 1.22x | $-7.58 Million |
| 1996 | -411.76% | -1400.00% | 0.18x | 1.65x | $-7.17 Million |
| 1997 | 0.00% | -1900.00% | 0.71x | 0.00x | $-9.28 Million |
| 1998 | -2657.14% | -4650.00% | 0.14x | 4.14x | $-18.67 Million |
| 1999 | -2590.60% | -4352.97% | 0.08x | 7.52x | $-17.45 Million |
| 2000 | 0.00% | -1137.68% | 0.09x | 0.00x | $-5.72 Million |
| 2001 | 0.00% | -1084.45% | 0.43x | 0.00x | $-8.57 Million |
| 2002 | 0.00% | -86175.82% | 0.01x | 0.00x | $-7.08 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.29 Million |
| 2006 | -34.78% | 0.00% | 0.00x | 1.06x | $-5.28 Million |
| 2007 | -82.81% | 0.00% | 0.00x | 1.14x | $-11.09 Million |
| 2008 | -106.51% | 0.00% | 0.00x | 1.09x | $-7.88 Million |
| 2009 | -105.28% | -3619.60% | 0.03x | 1.15x | $-4.09 Million |
| 2010 | -47.82% | -54.07% | 0.77x | 1.15x | $-2.07 Million |
| 2011 | -115.44% | 0.00% | 0.00x | 1.06x | $-8.85 Million |
| 2012 | -131.01% | 0.00% | 0.00x | 1.03x | $-18.37 Million |
| 2013 | -80.87% | 0.00% | 0.00x | 1.07x | $-13.84 Million |
| 2014 | -207.03% | 0.00% | 0.00x | 2.00x | $-20.74 Million |
| 2015 | -272.49% | 0.00% | 0.00x | 1.92x | $-45.34 Million |
| 2016 | -708.84% | 0.00% | 0.00x | 5.85x | $-27.64 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.02 Million |
| 2018 | -45.52% | 0.00% | 0.00x | 1.03x | $-16.30 Million |
| 2019 | -106.53% | 0.00% | 0.00x | 1.20x | $-16.74 Million |
| 2020 | -125.05% | 0.00% | 0.00x | 1.05x | $-10.85 Million |
| 2021 | -21.67% | 0.00% | 0.00x | 1.08x | $-20.71 Million |
| 2022 | -36.08% | 0.00% | 0.00x | 1.32x | $-25.14 Million |
| 2023 | -46.22% | 0.00% | 0.00x | 1.39x | $-22.32 Million |
| 2024 | -134.54% | 0.00% | 0.00x | 1.85x | $-27.56 Million |
| 2025 | -164.14% | 0.00% | 0.00x | 2.49x | $-26.79 Million |
Industry Comparison
This section compares Theriva Biologics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,374,297
- Average return on equity (ROE) among peers: -386.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Theriva Biologics Inc. (TOVX) | $15.40 Million | -229.41% | 1.48x | $13.61 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $98.20 Million |
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | -12.83% | 0.19x | $1.57 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $313.99 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $179.85 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $793.56 Million |
| Arbutus Biopharma Corp (ABUS) | $26.88 Million | -30.41% | 0.07x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $84.98 Million | -24.53% | 0.28x | $3.65 Billion |
About Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcin… Read more